The medical-tourism market is a denial-arbitrage market.
The medical-tourism market is projected to grow $85.9 billion through 2028 at a 32% compound annual rate. The trade-press framing is that cost arbitrage drives the market: U.S. patients fly to Thailand, India, Mexico, or Colombia because the procedure costs a fraction of the U.S. price.
The cost-arbitrage framing is partly correct and missing the structural driver.
What actually drives the market in 2025 is _coverage-gap arbitrage_. The patient who flies to Bangkok for a hip replacement is not primarily flying because Bangkok is cheap. They are flying because their U.S. insurer denied the procedure, the appeal process took six months, the procedure was still denied after appeal, and their alternative was either to pay U.S. cash price ($75,000-150,000) or to fly to a JCI-accredited hospital in Bangkok and pay $15,000-25,000 cash. The cash-price gap is real. The driver is the denial.
That distinction matters because the denial-rate trend is structural, not cyclical. AI-driven utilization-management has compressed the time from claim submission to denial to under a week at most large payers. The denial rate has risen modestly, the appeal-overturn rate has risen modestly, and the time-to-final-decision has compressed by half across the 2022-2024 window. The patient population sitting in the denied-and-appealing pool is larger and resolves faster than it did. Some fraction of that pool, instead of waiting for the U.S. system to resolve, books a flight.
The medical-tourism market, in operating terms, sits downstream of the U.S. denial-management apparatus.
The cohort flying for procedures has shifted with the driver. Through 2018-2022 the medical-tourism cohort skewed toward elective procedures (cosmetic surgery, dental, fertility, IVF). Through 2024-2025 the cohort has shifted toward medically-necessary procedures (joint replacements, cardiac procedures, oncology second-opinions and treatments) that the U.S. system denied or made unaffordable. The international-hospital category is now serving a different patient mix, with different clinical-acuity needs, different risk profiles, and different expectations of post-procedure follow-up.
The travel-and-healthcare integration layer that the cohort needs is genuinely new. The patient flying to Bangkok for a hip replacement needs flight, accommodation, hospital admission, post-op recovery housing, return-flight scheduling tied to recovery milestones, prescription handling, and home-country follow-up coordination. The current medical-tourism operators (Medical Tourism Magazine, Health-Tourism.com, the long tail of country-specific facilitators) handle some of those badly. The integrated platform that handles all of them well does not exist at scale. The operator who builds it captures a $10-20B annual revenue category by 2028.
The U.S. policy frame has not engaged with the implications. The patient who flies internationally to receive medically-necessary care is, on every measure that matters, a U.S. policy failure. The patient population is mostly middle-class working Americans whose insurance denied a covered procedure on technical grounds, not high-income patients seeking premium care. The cohort cost is paid in lost work time, post-procedure complications when the home-country system has to handle follow-up of an international procedure, and the documented mortality differential when a patient with comorbidities flies to receive care that should have been delivered domestically. None of that shows up in U.S. policy discussion. The trade-press version of medical tourism is a personal-finance feature. The structural version is a policy failure.
The denial-arbitrage market is a feature of the U.S. healthcare-system's coverage gap. The market exists because the gap exists. As AI-driven denial management compresses the time-to-denial and tightens the criteria, the gap widens, and the market grows. Operators in either travel or healthcare betting on this category are betting against the U.S. system's ability to close the gap, which is a defensible bet on the available evidence.
The cohort cost is paid by the patients who fly. Some of them get great care abroad and return home with better outcomes than they would have had in the U.S. system. Some of them have complications the home-country follow-up cannot handle, and the gap between the international procedure and the domestic follow-up apparatus produces the worse outcome. The structural failure is not that some patients fly. The structural failure is that the system that produced the denial is the system that should have produced the procedure, and the patient is the one absorbing the gap.
Cut through the trade-press framing and the picture sharpens. Medical tourism is the visible market that sits at the intersection of two underlying failures: U.S. denial-management aggressiveness and the coverage-gap that produces. The market grows because the failures grow. The integrated travel-healthcare platform is a real category, the cohort is real, and the policy class has not engaged with the implications. By 2028 the category will be twice the current size. The patients flying are the patients the U.S. system has already left behind. That, of course, is the part the trade-press framing does not say out loud.
—TJ